Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

Oracle’s Stock Seeks Footing Amid High-Stakes Cloud Investment

Robert Sasse by Robert Sasse
December 28, 2025
in AI & Quantum Computing, Analysis, Earnings, Tech & Software
0
Oracle Stock
0
SHARES
16
VIEWS
Share on FacebookShare on Twitter

Oracle Corporation’s shares have been navigating volatile territory, with recent developments presenting a complex picture for investors. The stock’s trajectory now hinges on a critical balancing act: can the company’s aggressive push into artificial intelligence infrastructure justify its substantial capital commitments, or will financial pressures overshadow its growth narrative?

The Cloud Revenue Anchor: TikTok Partnership Finalized

A significant factor contributing to recent price stability is the confirmed strategic partnership with TikTok. A consortium led by Oracle has formally agreed to acquire a stake in the video platform’s U.S. operations, with Oracle itself slated to hold approximately 15%. The transaction is scheduled for finalization on January 22, 2026.

Beyond the equity position, the core of the deal for Oracle is technological. TikTok has committed to a “take-or-pay” agreement, anchoring its business to the Oracle Cloud Infrastructure (OCI). This arrangement not only guarantees long-term revenue streams for Oracle’s cloud division but also alleviates market concerns about the potential loss of this high-profile anchor client for its AI-driven services.

Soaring Ambitions, Soaring Costs

Despite this positive strategic development, investor sentiment remains tempered by the aftermath of the latest quarterly report. Since reaching an all-time high near $345 in September, the equity has surrendered significant value. The primary catalyst for this sell-off was not operational performance but rather a shock from the expenditure side: management unveiled plans for capital investments (CapEx) totaling $50 billion for the 2026 fiscal year.

This figure substantially exceeded market expectations, raising immediate questions about balance sheet health. Unlike deep-pocketed rivals such as Microsoft or Amazon, Oracle is expected to fund this massive outlay through a heavier reliance on debt financing and its operating cash flow. This uncertainty has even sparked legal scrutiny, with law firms reportedly investigating potential class actions centered on whether the capital-intensive nature of Oracle’s AI contracts was adequately disclosed to shareholders.

Should investors sell immediately? Or is it worth buying Oracle?

On the revenue front, the trend remains robust. Cloud segment revenue surged 68% in the last reporting period, fueled by exceptionally high demand for GPU capacity.

Technical Levels and Forward Outlook

Closing at $197.99 on Friday, the stock now faces a key technical juncture. The $200 level represents a significant psychological and technical resistance point. A sustained breakout above this barrier could indicate that the recent phase of capitulation selling has concluded, potentially attracting value-oriented buyers back to the market.

Conversely, should the recovery attempt falter, support near $190 becomes the next focal point. A breach below this level would likely reignite selling pressure.

  • Recent Close: $197.99 (+0.25%)
  • Distance from 52-Week High: -29.47%
  • 14-Day RSI: 69.3

The next concrete milestone for the market is the aforementioned January 22, 2026 date for the TikTok deal closure. In the interim, Oracle must demonstrate that its monumental investments can be converted into profitable growth swiftly enough to justify its current valuation, which remains elevated compared to historical averages.

Ad

Oracle Stock: Buy or Sell?! New Oracle Analysis from February 8 delivers the answer:

The latest Oracle figures speak for themselves: Urgent action needed for Oracle investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

Oracle: Buy or sell? Read more here...

Tags: Oracle
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Quanterix Stock
Analysis

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Next Post
Alphabet Stock

Alphabet Shares Approach Peak Amid Autonomous Driving Setback

Netflix Stock

Netflix's Strategic Pivot: A High-Stakes Bid for Warner Bros. Discovery

BioNTech Stock

BioNTech Consolidates mRNA Leadership with Strategic CureVac Acquisition

Recommended

Biotechnology Stock Exchange

Analysts Bullish on Dynatrace with Price Targets on the Rise

2 years ago
The Trade Desk Stock

The Trade Desk Faces Mounting Pressure as Amazon Strikes Netflix Deal

5 months ago

Analyst Reaffirms Buy Rating on International Seaways with 66 Price Target

2 years ago
Biotechnology Stock Bull Market

KeyBanc Analyst Raises Price Target and Maintains Overweight Rating on Repligen NASDAQ RGEN

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Trending

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

by Jackson Burston
February 8, 2026
0

Investor attention is now firmly fixed on February 26, 2026, as Puma Biotechnology prepares to release its...

Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test
  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com